NEUP
Neuphoria Therapeutics IncKey Statistics
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company at the forefront of developing pioneering therapies for mental health disorders utilizing psychedelic compounds and cutting-edge drug delivery technologies. With a robust pipeline of preclinical candidates, Neuphoria is strategically positioned to address critical unmet needs in mental health care, reflecting the growing demand for effective treatment options in this sector. As a leader in the expanding psychedelic therapy market, Neuphoria presents a unique investment opportunity for institutional investors looking to capitalize on transformative trends in healthcare that have the potential to redefine the treatment landscape for mental health conditions.
Fundamentals
| Revenue (TTM) | -13,267 |
| Gross Profit (TTM) | -13,267 |
| EBITDA | $-14.00M |
| Operating Margin | 110513.00% |
| Return on Equity | -62.90% |
| Return on Assets | -28.00% |
| Revenue/Share (TTM) | $-0.00 |
| Book Value | $5.47 |
| Price-to-Book | 1.00 |
| Price-to-Sales (TTM) | 1.70 |
| EV/Revenue | 0.224 |
| EV/EBITDA | -0.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $5.40M |
| Float | $4.19M |
| % Insiders | 7.70% |
| % Institutions | 55.03% |
Historical Volatility
Volatility is currently expanding